METAVIA RSS Feed | Nachrichten - www.finanzen.net

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Eff...

Mon, 05 Jan 2026 14:30:00 +0100

Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54

Significant Direct Hepatic Activity with a 23.7% ...

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Mon, 29 Dec 2025 14:31:00 +0100

CAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mon, 22 Dec 2025 14:31:00 +0100

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Tue, 02 Dec 2025 14:45:00 +0100

CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or ...

MetaVia präsentierte Quartalsergebnisse

Sun, 09 Nov 2025 06:35:07 +0100

MetaVia ließ sich am 06.11.2025 in die Bücher schauen: Auf der vierteljährlichen Finanzkonferenz hat MetaVia die Bilanz zum am 30.09.2025 beendeten Jahresviertel offengelegt.Das EPS wurde auf einen Verlust von 0,14 ...

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Fri, 07 Nov 2025 14:31:00 +0100

Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Thu, 06 Nov 2025 14:31:00 +0100

Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data ...

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Tue, 04 Nov 2025 22:01:00 +0100

New Phase 1 PK DataSupport Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration
DA-1726 Achieves ...

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Mon, 27 Oct 2025 13:31:00 +0100

CAMBRIDGE, Mass., Oct. 27, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Mon, 20 Oct 2025 14:31:00 +0200

CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...